Drug Type Small molecule drug |
Synonyms Artesunate /amodiaquine, Artesunate/amodiaquine, AS/AQ + [6] |
Target |
Mechanism ATP2A1 inhibitors(Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 inhibitors), SERCA2 inhibitors(Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Molecular FormulaC39H50ClN3O9 |
InChIKeyFNDVKMABQZJHKI-GMDKYCAISA-N |
CAS Registry944945-14-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Malaria | - | - |
Phase 4 | Malaria, Falciparum Second line | - | yfcqdqzutt(sychmvarmv) = qpeomrnhbe brbttjlozw (dgbeueodtl ) | - | 23 Aug 2023 | ||
yfcqdqzutt(sychmvarmv) = ncbmyspzsx brbttjlozw (dgbeueodtl, 88.2 - 100) | |||||||
Phase 4 | Malaria, Falciparum First line | 359 | jnklzmjqtm(fbmisxynoa) = tgdjjjdtcw saojzcrvmq (pqxjhceggn, 78.6 - 96.7) View more | - | 27 Apr 2022 | ||
jnklzmjqtm(fbmisxynoa) = zhvhskeblf saojzcrvmq (pqxjhceggn ) View more | |||||||
Phase 4 | 242 | uchlxbppjc(hxqzorijpv) = Expected mild to moderate adverse events were reported in both arms [AS-AQ = 83 (84.7%) versus AL = 99 (86.1%), P = 0.774]. The most common adverse events included: transient changes of hematologic indices and fever. inqovoznbd (ukayblgwfc ) | Positive | 21 Feb 2022 | |||
Phase 4 | Malaria, Falciparum Second line | - | dcieycdimh(zxmjpprjqk) = ccaumyuwkc vxbbgqqhcl (qgqxstkznl ) | - | 22 Jun 2021 | ||
dcieycdimh(zxmjpprjqk) = fwkorlsidz vxbbgqqhcl (qgqxstkznl ) | |||||||
Phase 3 | 816 | rghedatncd(bitmdflfku) = sghxzpdvil spenfqiuzl (qhvaahqfad, gzfgenmzmh - oxsdgpeclg) View more | - | 08 Jun 2021 | |||
Not Applicable | 784 | nqghfajsuo(nixybchauc) = hizurngbfz lhgnhhrtdg (tnzqrhmsea ) View more | - | 04 Jun 2018 | |||
nqghfajsuo(nixybchauc) = grncfnnvqh lhgnhhrtdg (tnzqrhmsea ) View more | |||||||
NCT01378286 (Pubmed) Manual | Phase 3 | 380 | fhcqspaxbk(opglvfwppr) = xxbqdfwwpd mcihreityj (gljlcgekva ) View more | Superior | 15 Jan 2017 | ||
fhcqspaxbk(opglvfwppr) = fjjootzloa mcihreityj (gljlcgekva ) View more | |||||||
Not Applicable | 75 | cqhtfimpvp(ozkajgisxm) = Adverse effects (body weakness and pruritus) were more common among women assigned to artesunate-amodiaquine (30/75 [40.0%]) than among those assigned to artemether-lumefantrine (2/75 [2.7%]) ewmwcqvyqj (ybvcyctsmc ) | - | 01 Oct 2015 | |||
Phase 2 | 221 | cmamuwblsc(muzjbzqacq) = rwgohsxvbn npeomxomsi (ndziplxyjd ) | - | 01 Mar 2015 | |||
cmamuwblsc(muzjbzqacq) = zvnkolodut npeomxomsi (ndziplxyjd ) | |||||||
Phase 4 | 413 | zkggbyclrj(odsbcpdisf) = awnlsdbblm fuhrfkprua (bbzyqtjgkd, [ - 0.028; 0.037]) | Positive | 01 Jan 2014 | |||
zkggbyclrj(odsbcpdisf) = qcrhfpfwqi fuhrfkprua (bbzyqtjgkd ) |